Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Vaginal Atrophy 1Urogenital Abnormalities 1Urinary Tract Infections 1Dysuria 1Dyspareunia 1Breast Neoplasms 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Replens × Clear all
NCT01984138 2026-01-28

REVIVE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Breast

Breast Neoplasms

NCT04493333 2024-11-27

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

University of Arkansas

Phase 2 Terminated
8 enrolled 11 charts
Breast

Vaginal Atrophy

NCT03185169 2018-07-26

GSM

Alta Bates Summit Medical Center

Phase EARLY_PHASE1 Terminated
14 enrolled

Dyspareunia, Urinary Tract Infections, Urogenital Abnormalities, Dysuria

Data powered by HemOnc (CC BY 4.0) Colophon âš¡